Advisor AgreementAdvisor Agreement • August 8th, 2024 • Verve Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Advisor Agreement (the “Agreement”), made this 30th day of May, 2024, is entered into by and between Verve Therapeutics, Inc. (the “Company”), and Andrew Bellinger (the “Advisor”), and will be effective as of the day immediately following the Separation Date (hereinafter, the “Effective Date”). Capitalized terms used but not defined herein have the meanings set forth in the letter agreement to which this Agreement is attached as Attachment A (the “Separation Agreement”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.Advisor Agreement • August 8th, 2024 • Verve Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This letter agreement memorializes our discussions about your transition and separation from Verve Therapeutics, Inc. (the “Company”). As we discussed, provided you (a) sign and return to me, no later than the close of business on May 30, 2024, this letter agreement and the Advisor Agreement (as defined below), (b) do not rescind your acceptance of this letter agreement within seven (7) business days thereafter, (c) sign and return on, but not before, the Separation Date (as defined below) the Additional Release of Claims attached hereto as Attachment B (the “Additional Release”), (d) do not revoke your acceptance of the Additional Release within seven (7) calendar days thereafter (the “Additional Release Revocation Period”), and (e) comply with the obligations set forth in Sections 3, 4, 5 and 6 herein and in the Additional Release (the foregoing provisions (a) through (e) collectively, the “Severance Conditions”), you will remain an employee of the Company, pursuant to the terms and
